Pfizer expands use of Linguamatics I2E
Pfizer has extended its strategic collaboration with Linguamatics to use the I2E knowledge discovery platform for text mining across its R&D organisation.
Pfizer researchers and other decision-makers will use I2E to discover and extract key facts and relationships from internal and external literature sources to support decision-making. Financial details of the agreement were not disclosed.
‘High performance text mining is strategically important for any global pharma company, and especially a market leader like Pfizer,’ said Giles Day, senior director of R&D Informatics, Pfizer. ‘Our expanded collaboration with Linguamatics underlines our commitment to exploit the value of intelligence from text within our R&D operations. For example, the use of I2E supports our DKTP (Deep Knowledge of Targets and Pathways) strategy to find novel relationships between diseases and targets for rapid identification of therapeutically relevant targets.’
‘Linguamatics I2E has been used to date for focused knowledge discovery from large document collections in a variety of R&D applications at Pfizer,’ added David de Graaf, director systems biology, Pfizer. ‘We are now also applying its agile NLP-based querying to inform research decisions within the new Biotherapeutics and Bioinnovation Center.’